888-427-0885
The Eli Lilly AWARD-PEDS PLUS Type 2 Diabetes Research Study for Children & Teens is Enrolling
This study is enrolling children ages 10 to 17 years of age to help assess dulaglutide*—
A medicine that’s
FDA-approved to treat T2
diabetes in this age group.
Now, however, researchers want to see if (when given at higher investigational doses) it can help to better control the condition in children/teens whose blood sugar (HbA1c) remains high despite treatment.
*Though dulaglutide (Trulicity®) is an approved T2D medication, it is considered “investigational” in this study because researchers are assessing it at higher doses than those previously approved for use in this age group.
This study is enrolling children ages 10 to 17 years of age to help assess dulaglutide*—
A medicine that’s FDA-approved
to treat T2 diabetes in this age group.
Now, however, researchers want to see if (when given at higher investigational doses) it can help to better control the condition in children/teens whose blood sugar (HbA1c) remains high despite treatment.
*Though dulaglutide (Trulicity®) is an approved T2D medication, it is considered “investigational” in this study because researchers are assessing it at higher doses than those previously approved for use in this age group.
To qualify your child must:
- Be 10 to 17 years of age
- Have a diagnosis of Type 2 diabetes (T2D)
- Be on a standard diet and exercise program and take:
- Metformin
- Basal insulin OR
- Metformin AND basal insulin - Have high HbA1c despite above treatment
Check now to see if your child may qualify!
Those who qualify may receive*:
- No-cost study medication
- No-cost study-related care
- Payment up to $100
To qualify your child must:
- Be 10 to 17 years of age
- Have a diagnosis of Type 2 diabetes (T2D)
- Be on a standard diet and exercise program and take:
- Metformin
- Basal insulin OR
- Metformin AND basal insulin - Have high HbA1c despite above treatment
Check now to see if your child may qualify!
Those who qualify may receive*:
- No-cost study medication
- No-cost study-related care
- Payment up to $100
Take the next step to see if your child may qualify for this pediatric research.
But don’t delay — space is limited!
Why is the AWARD-PEDS PLUS study on Type 2 diabetes (T2D) in children important?
With type 2 diabetes, the body EITHER doesn’t make enough insulin OR can’t use insulin properly OR both. This results in a build-up of sugar/glucose in the blood (referred to as HbA1c or A1c on lab tests). Over time, high blood sugar can cause serious health problems and do damage to organs including the heart, eyes and kidneys.
Though more common in adults, the diagnosis of Type 2 diabetes in U.S. children has been on the rise — which means it has even more time to affect the body.
Yet children and teens with T2D have fewer approved glucose-lowering treatment options compared to adults — and it progresses faster, which can result in more health issues at a younger age.
Thus, there is an important unmet need for more options to treat children and adolescents with T2D, especially in those with high glucose despite treatment.
If your child has T2D that is not well-controlled, consider enrolling them in this study. The first step is to see if they may qualify. Know that even if your child does qualify and is enrolled, you can still withdraw them from the study at any time, for any reason.
Act now.
How does it work?
Answer some questions
about your child or teen’s health
Tell us a little bit
about your child/teen
Connect to a study
in your area
Just takes a few minutes
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
©2023 Acurian, Inc. All rights reserved.
*In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/
research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.